In a nutshell This study investigated whether lenalidomide maintenance therapy after intensive chemoimmunotherapy and first-line autologous hematopoietic stem-cell transplantation (AHSCT) improved the outcomes of patients with mantle cell lymphoma (MCL). The data showed that lenalidomide maintenance after AHSCT improved the survival without...
Read More
In a nutshell This study assessed the effectiveness and safety of geptanolimab (GB226) in relapsed/refractory (r/r) peripheral T cell lymphoma (PTCL). The authors concluded that geptanolimab showed promising activity and manageable safety in these patients. Some background Peripheral T cell lymphoma (PTCL) is a rare subtype of non-Hodgkin...
Read More
In a nutshell This study reported the long-term effectiveness and safety outcomes of treatment with idelalisib (Zydelig) after a longer follow-up of patients with indolent (painless) non-Hodgkin lymphoma. The data showed that idelalisib treatment improved the overall survival of these patients in the long-term. Some background Non-Hodgkin...
Read More
In a nutshell This study investigated the effectiveness and safety of GDP (gemcitabine, dexamethasone, and cisplatin) and ICE (ifosfamide, carboplatin, and etoposide) regimens as salvage therapy in patients with relapsed/refractory aggressive lymphoma. The data showed that both the GDP and ICE regimens are suitable options for relapsed/refractory...
Read More
In a nutshell This study aimed to investigate the effect of chemotherapy dose intensity on outcomes for patients with adult T-cell leukemia/lymphoma. This study concluded that higher chemotherapy dose intensity improves outcomes for these patients. Some background Adult T-cell leukemia/lymphoma (ATL) is an aggressive blood cancer. It can...
Read More
In a nutshell This study aimed to evaluate the safety and effectiveness of loncastuximab tesirine (LoT; Lonca) for the treatment of patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The study found that LoT was safe and had promising activity in these patients. Some background B-NHL is a type of...
Read More
In a nutshell This study aimed to investigate the combination of bendamustine (Treanda), ofatumumab (Arzerra), carboplatin (Paraplatin), and etoposide (Etopophos) in patients with relapsed/refractory aggressive non-Hodgkin lymphoma (NHL). This study concluded that this combination was safe and effective in these...
Read More
In a nutshell The study analyzed outcomes of high-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (AHSCT) for patients with non-Hodgkin lymphoma (NHL) in a resource-limited country and evaluated whether upfront AHSCT could be an effective treatment. The authors found promising outcomes of this treatment in a resource-limited...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of tisagenlecleucel (TL; Kymriah) in a real-world setting as a treatment for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). This study concluded that TL has similar effectiveness and improved safety in a real-world setting when compared to a trial...
Read More
In a nutshell This study aimed to investigate if tazemetostat (Tazverik) was a safe and effective treatment in patients with relapsed/refractory follicular lymphoma (FL). This study concluded that tazemetostat provided durable responses and was well tolerated in these patients. Some background Tazemetostat is...
Read More
In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). This study concluded that this combination was well tolerated and had promising responses in these patients. Some...
Read More
In a nutshell This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma. This study concluded that this treatment path is feasible and a good treatment alternative for these patients. Some background Allogenic...
Read More
